FOLH1 and posterior cortical atrophy: PSMA‐PET/CT is only cautiously introduced in the international guidelines for primary staging of intermediate‐ and high‐risk PCa patients because of lack of evidence of whether the increased sensitivity will translate into patient benefit of being staged with this more sensitive modality.11